Released on: July 12, 2008, 12:06 am

Press Release Author: Brand-Comm

Industry: Healthcare

Press Release Summary: Stempeutics Research Pvt. Ltd, a Bangalore based Stem Cell
Company is expanding its footprints both nationally and internationally. Stempeutics
today inaugurated its second Stem Cell research & therapeutics facility at the
Manipal University campus.

Press Release Body: . Facility will be used for advanced stem cell research in human
embryonic stem cells in collaboration with Manipal Assisted Reproduction Center
. Plans for establishing large scale production of Mesenchymal Stem Cells for
Clinical Trials using innovative upscaling process
. Plans to conduct pilot studies to address the needs of patients suffering with
critical diseases like Dilated Cardio Myopathy, End Stage Liver Disease and
Osteoarthritis
Bangalore, July 11th 2008 - Stempeutics Research Pvt. Ltd, a Bangalore based Stem
Cell Company is expanding its footprints both nationally and internationally.
Stempeutics today inaugurated its second Stem Cell research & therapeutics facility
at the Manipal University campus. Supported by University, the state-of-the-art
facility located at Shirdi Sai Baba Cancer Hospital is conceived to further leverage
the research & clinical experience gained and also to address the needs of patients
with limited treatment options for the conditions like Dilated Cardio Myopathy, End
Stage Lever Disease and Osteoarthritis. First Lab was established in Bangalore in
2006.
Stempeutics manufacturing facility at Manipal is cGMP (current Good Manufacturing
Practice) compliant. The facility is close to 5000 sq ft big with the state-of-art
laboratory equipments and two class 10K clean rooms. It has been designed to meet
the future plan of accreditation requirements of the USA Foundation for the
Accreditation of cellular therapy (FACT) and the manufacturing process will adhere
to cGTP (current Good Tissue Practice).

Stempeutics is committed to develop and deliver safe and effective stem cell therapy
for the diseases where there is no cure. It is committed to helping patients by
carrying out cutting edge research at its highest standards. Current focus is on
bone marrow derived adult mesenchymal stem cells. Initial emphasis is on autologous
cell therapies - where the bone marrow is aspirated from the patient, stem cells are
isolated and upscaled and then injected back to the patient. So far the Bangalore
facility has conducted pilot studies on 100 plus patients covering various diseases.

Stempeutics goal is to develop allogenic stem cell therapy in the near future so as
to make this therapy more affordable, readily available off the shelf and also to be
used in critical conditions. Stempeutics is the first company to employ a global
hybrid model where by it offers both autologus and allogenic stem cell therapy for
various diseases.




Speaking at the Press conference, Dr Ramdas Pai, Chancellor, Manipal University said
"Stem Cell therapy is showing promising results for various diseases and it is
currently used where the conventional therapies could not cure the disease. Keeping
in mind the overall disease burden of various medical conditions and the potential
for stem cell therapy globally, we are setting up our third lab at Kuala Lumpur
Malaysia. Malaysia Lab will be operational in August 2008. With the expertise of the
Clinicians at Kasturba Medical College at Manipal and Mangalore, we will stand to
gain and realize the clinical value of stem cells".

Speaking at the Press conference Dr HS Ballal, Pro Chancellor, Manipal University
said "We are happy on Stempeutics's commitment in developing Manipal as one of the
Stem Cell Research and Therapy hubs. He said that Stempeutics should focus on CME
programs in latest developments in Stem Cells research and also conduct formal hands
on short term courses in Regenerative Medicine in collaboration with Manipal
University. He also added that the stem cell research should be conducted in
collaboration with various departments of the University with increased frequency of
publications and patent portfolios".

Speaking at the Press conference Mr B.N. Manohar, President, Stempeutics Research
said, "While the initial foray of Stempeutics is in bone marrow derived mesenchymal
stem cells, Stempeutics is investing heavily on its R&D to bring out some innovative
products (like tailor made progenitor cells) in the near future based on adult stem
cells. It is also investing money on its long term goal of leveraging human
embryonic stem cells for therapeutics purpose. Towards this goal Stempeutics will
work closely with Manipal Assisted Reproduction Center in Kasturba Hospital for
establishing human embryonic stem cells lines for advanced research. We want to
become an undisputed leader in the Stem Cell area in this part of the world".

Speaking at Press conference Dr Satish Totey, Chief Scientific Officer, Stempeutics
Research said, "Our mission is to ethically and scientifically explore the full
potential of stem cells to transform medicine and offer new hope to millions of
people. There will be continuous research for each disease so as to improve product
development for effective therapy. Research will be conducted on effective cell
number, route of transplantation etc. Further research will be carried out to
develop lineage specific cells or precursor cells for more effective therapy. He
said that Stempeutics will use the animal house at the University for doing Pre
Clinical studies".



Web Site: http://www.brand-comm.com

Contact Details: brand-comm
# 68, 1st Floor, Transpade Towers,
Jyothi Nivas College Road, Koramangala, Bangalore 560 095
(O): 91(80) 25539369